Radiopharm Theranostics Limited (RAD.AX)
- Previous Close
0.0450 - Open
0.0450 - Bid 0.0450 x --
- Ask 0.0460 x --
- Day's Range
0.0450 - 0.0460 - 52 Week Range
0.0430 - 0.2031 - Volume
602,878 - Avg. Volume
745,434 - Market Cap (intraday)
20.331M - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.70
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
www.radiopharmtheranostics.comRecent News: RAD.AX
Performance Overview: RAD.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RAD.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RAD.AX
Valuation Measures
Market Cap
20.33M
Enterprise Value
18.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.84
Enterprise Value/Revenue
63.06
Enterprise Value/EBITDA
-0.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.84%
Return on Equity (ttm)
-107.05%
Revenue (ttm)
6.01M
Net Income Avi to Common (ttm)
-46.82M
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.89M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-17.75M
Research Analysis: RAD.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker